Background and purpose Although erenumab has demonstrated significant reduction in
migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is …

Background The calcitonin gene-related peptide (CGRP) pathway is important in migraine
pathophysiology. We assessed the efficacy and safety of erenumab, a fully human …

Background Clinical trials have shown that erenumab is effective and well-tolerated for the
preventive treatment of chronic migraine. To extend the results from clinical trials, we …

Background We tested erenumab, a fully human monoclonal antibody that inhibits the
calcitonin gene–related peptide receptor, for the prevention of episodic migraine. Methods …

Background Erenumab was effective and well tolerated in a pivotal clinical trial of chronic
migraine. Here, we evaluated efficacy and safety of monthly erenumab (70 mg or 140 mg) …

Background Novel therapeutic options with improved efficacy and safety profiles are needed
for the prophylaxis of migraine. In recent years, the inhibition of calcitonin gene-related …

Background This study reports the long-term safety and efficacy of erenumab in chronic
migraine patients. Methods This was a 52-week open-label extension study of a 12-week …

Background A substantial proportion of patients with migraine does not respond to, or
cannot tolerate, oral preventive treatments. Erenumab is a novel CGRP-receptor antibody …

Objective A phase 2, double‐blind, placebo‐controlled study to evaluate the efficacy and
safety of erenumab for the prevention of episodic migraine in Japanese patients was …

During a 1-year compassionate use program, 156 patients with migraine self-administered a
monthly dose of erenumab 140 mg with a subcutaneous autoinjector. Main inclusion criteria …